HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.

AbstractBACKGROUND:
Niemann-Pick type C disease (NPC) is an inherited neurodegenerative disorder characterised by an intracellular lipid-trafficking defect with secondary accumulation of glycosphingolipids. Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis. Miglustat is able to cross the blood-brain barrier, and is thus a potential therapy for neurological diseases. We aimed to establish the effect of miglustat on several markers of NPC severity.
METHODS:
Patients aged 12 years or older who had NPC (n=29) were randomly assigned to receive either miglustat 200 mg three times a day (n=20) or standard care (n=9) for 12 months. 12 children younger than 12 years of age were included in an additional cohort; all received miglustat at a dose adjusted for body surface area. All participants were then treated with miglustat for an additional year in an extension study. The primary endpoint was horizontal saccadic eye movement (HSEM) velocity, based on its correlation with disease progression. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN26761144.
FINDINGS:
At 12 months, HSEM velocity had improved in patients treated with miglustat versus those receiving standard care; results were significant when patients taking benzodiazepines were excluded (p=0.028). Children showed an improvement in HSEM velocity of similar size at 12 months. Improvement in swallowing capacity, stable auditory acuity, and a slower deterioration in ambulatory index were also seen in treated patients older than 12 years. The safety and tolerability of miglustat 200 mg three times a day in study participants was consistent with previous trials in type I Gaucher disease, where half this dose was used.
INTERPRETATION:
Miglustat improves or stabilises several clinically relevant markers of NPC. This is the first agent studied in NPC for which there is both animal and clinical data supporting a disease modifying benefit.
AuthorsMarc C Patterson, Darleen Vecchio, Helena Prady, Larry Abel, James E Wraith
JournalThe Lancet. Neurology (Lancet Neurol) Vol. 6 Issue 9 Pg. 765-72 (Sep 2007) ISSN: 1474-4422 [Print] England
PMID17689147 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • 1-Deoxynojirimycin
  • miglustat
Topics
  • 1-Deoxynojirimycin (analogs & derivatives, therapeutic use)
  • Adolescent
  • Adult
  • Age Factors
  • Analysis of Variance
  • Child
  • Child, Preschool
  • Cohort Studies
  • Deglutition (drug effects)
  • Double-Blind Method
  • Drug Administration Schedule
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Humans
  • Male
  • Niemann-Pick Disease, Type C (drug therapy, physiopathology)
  • Retrospective Studies
  • Saccades (drug effects)
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: